Last Updated: June 24, 2026

Suppliers and packagers for FENTANYL-87

✉ Email this page to a colleague

« Back to Dashboard

FENTANYL-87

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Difgen Pharms	FENTANYL-87	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	077449	ANDA	Aveva Drug Delivery Systems Inc.	3215-7701-05	5 POUCH in 1 CARTON (3215-7701-05) / 1 PATCH in 1 POUCH (3215-7701-01) / 72 h in 1 PATCH	2025-01-30
Difgen Pharms	FENTANYL-87	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	077449	ANDA	Aveva Drug Delivery Systems Inc.	3215-7702-05	5 POUCH in 1 CARTON (3215-7702-05) / 1 PATCH in 1 POUCH (3215-7702-01) / 72 h in 1 PATCH	2025-01-22
Difgen Pharms	FENTANYL-87	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	077449	ANDA	Aveva Drug Delivery Systems Inc.	3215-7703-05	5 POUCH in 1 CARTON (3215-7703-05) / 1 PATCH in 1 POUCH (3215-7703-01) / 72 h in 1 PATCH	2025-02-05
Difgen Pharms	FENTANYL-87	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	077449	ANDA	Aveva Drug Delivery Systems Inc.	3215-7704-05	5 POUCH in 1 CARTON (3215-7704-05) / 1 PATCH in 1 POUCH (3215-7704-01) / 72 h in 1 PATCH	2025-01-06
Difgen Pharms	FENTANYL-87	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	077449	ANDA	Aveva Drug Delivery Systems Inc.	3215-7705-05	5 POUCH in 1 CARTON (3215-7705-05) / 1 PATCH in 1 POUCH (3215-7705-01) / 72 h in 1 PATCH	2025-02-10
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Suppliers and packagers for FENTANYL-87

Last updated: June 9, 2026

Fentanyl-87 Suppliers: Who Manufactures and Supplies Fentanyl 87 (API, Intermediates, and Finished-Dose Inputs)?

No sourcing, supplier, or procurement details are provided for “fentanyl-87” as a distinct pharmaceutical product name or active ingredient (API) under that exact label. Without an unambiguous product identity (e.g., FDA SPL name and/or INN/salt form and strength), supplier lists would be inaccurate and operationally unusable.

What suppliers make “fentanyl-87” API (active pharmaceutical ingredient)?

No complete, reliable supplier mapping can be produced because “fentanyl-87” is not a standard, globally recognized API designation. Without the specific API identity (fentanyl base vs citrate vs hydrochloride; and whether “87” denotes a strength, salt code, or internal reference), API manufacturer coverage cannot be confirmed.

Which API manufacturers supply fentanyl citrate or fentanyl hydrochloride?

No response.

Which intermediate suppliers support fentanyl API production?

No response.

Who supplies fentanyl-87 finished-dose products (patches, tablets, lozenges, injections)?

No response.

Which distributors supply fentanyl transdermal systems?

No response.

Which distributors supply fentanyl injection and nasal/transmucosal products?

No response.

What is the FDA regulatory status of “fentanyl-87” (Orange Book listings)?

No response.

Does “fentanyl-87” face generic or biosimilar supply substitution risk?

No response.

What patent estate or exclusivity restricts suppliers for fentanyl-87?

No response.

Which companies compete for fentanyl supply by dosage form?

No response.

How do procurement and manufacturing compliance requirements affect fentanyl-87 sourcing?

No response.

What is the market concentration of fentanyl suppliers (API and finished goods)?

No response.

How to validate a “fentanyl-87” supplier (GMP, DEA registration, quality agreements)?

No response.

Key Takeaways

No sourcing intelligence can be generated for “fentanyl-87” without a precise, unambiguous product identifier tied to the exact API, salt form, dosage form, and regulatory listing.

FAQs

What does “fentanyl-87” refer to in FDA or product labeling?
Which fentanyl salt form is most commonly sourced for API procurement?
How are fentanyl suppliers vetted for GMP and DEA-compliant distribution?
What dosage forms most affect supplier eligibility and lead times for fentanyl?
How do controlled-substance supply constraints shift between API and finished-dose procurement?

References (APA)

No references.

More… ↓

⤷ Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.